7 results about "Vascular obstruction" patented technology

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The disclosed technology relates to a catheter configured to reduce microvascular obstruction (MVO) in myocardial tissue at risk due to an acute myocardial infarction (AMI). The catheter comprises a catheter shaft that is configured to be inserted into a heart of a patient. A channel is arranged in the heart and is configured to deliver blood from a first location in the heart to a second location in the heart. A pressure sensor is configured to monitor pressure at the second location to ensure controlled delivery of blood from the first location to the second location. The catheter device is operable to reduce the amount of tissue actually comprising MVO by approximately 20% compared to untreated regions.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

The invention relates to the technical field of medical image processing and analysis, in particular to a cardiovascular image analysis system which comprises the steps that image collection is conducted on a target blood vessel through angiocardiography equipment, a time sequence image sequence is formed, and the contrast agent injection time and the heart rate are synchronously recorded; calculating a pixel displacement field based on a time sequence image sequence, obtaining displacement through local pixel gray matching, forming a motion vector containing direction and distance, indirectly quantifying the blood flow velocity, then converting into a blood flow topological graph, coding the flow velocity by vector arrows and colors, and forming a continuous path through streamline interpolation; the vorticity is calculated through the spatial change rate of the flow velocity component, a vortex region is calculated and defined according to the vorticity, and a vortex breaking point is positioned in the region by using an extreme point detection algorithm; and constructing a narrow correlation index based on the vortex breaking point density and the blood flow breaking line length, and judging the blood vessel obstruction degree according to an index interval. Based on the correlation index, objective evaluation criteria are provided for stenosis of different degrees.

The present invention provides an application of a sardine peptide composition in a drug for treating allergic rhinitis. The sardine peptide composition is a mixture of dipeptide to pentapeptide of sardine. The biological activities of various peptide fragments are synergistic. The sardine medicine composition has the effects of inhibiting nasal cavity inflammation attack and preventing nasal cavity capillary obstruction, and can also improve rhinocnesmus, sneezing, rhinorrhea and nasal obstruction caused by allergic rhinitis, as well as various symptoms accompanied with itching of palate, throat, ears and eyes, red and swollen eyes and water secretions. Meanwhile, the sardine peptide composition has no irritation to patients with nasal mucous membrane sensitivity, systemic side effects such as local side effects and drowsiness are not observed, and the sardine peptide composition has excellent effectiveness and safety.

The disclosed technology relates to methods of preventing or limiting effects of heart failure in a human patient that has sustained acute myocardial infarction. The method includes determining that the patient is exhibiting acute myocardial infarction, inserting a transvalvular pump at least partially into a heart of the patient, and operating the transvalvular pump to cause blood to flow at a rate of at least 2.5 L / min for at least a support period. The method further includes performing a reperfusion of the patient's heart to restore blood flow to the heart after at least the support period has ended and reducing the amount of tissue actually comprising microvascular obstruction (MVO) of tissue that is at risk of MVO by approximately 20%.